… Using the developed model, we were able to show that … Monitoring of an eculizumab
concentration or classical pathway … In case monitoring of eculizumab concentrations or classical …

… and management of atypical hemolytic uremic syndrome (… aHUS has been established as
a prototypic disease resulting … of C5 blockade in the treatment of this devastating disease. C5 …

… An international consensus approach to the management of atypical hemolytic uremic
syndrome in children. Pediatric Nephrology. 2016;31(1):15-39 and Fakhouri F, Zuber J, Fremeaux-…

… The study was conducted in a one compartment model with nine patients receiving …
Monitoring of eculizumab therapy and complement activity in atypical hemolytic uremic syndrome …

… current treatment protocol is based on restrictive use of eculizumab. Prospective monitoring
… Following their model, it would be possible to extend the interval to 4 weeks in patients less …

… in atypical hemolytic uremic syndrome (aHUS) while reducing dosing frequency (every 8 vs
2 weeks, respectively). Treatment choice … of ravulizumab and eculizumab for treating aHUS. …

Atypical hemolytic uremic syndrome (aHUS) is an ultrarare disease caused, in most cases,
by dysregulation of the alternative complement (C′) pathway at the surface of the vascular …

… either recurrent or de novo atypical haemolytic uraemic syndrome (aHUS). According to
previous studies, eculizumab (ECU) is effective for prophylaxis and for treatment of recurrence. …

… using Cox proportional hazards regression models. Patients were censored at … monitoring
plan approach is being implemented in some centers using the genetic profile and monitoring …

… such a model and explored alternative dosing regimens to improve early treatment response
… observational study to monitor the new guideline concerning the treatment of patients with …